With USPTO Re-Exam Over, ExonHit and Jivan Likely to Resume Splice-Array Litigation | GenomeWeb

By Justin Petrone

The United States Patent and Trademark Office has concluded its reexamination of a patent held by ExonHit Therapeutics that is central to an ongoing IP infringement lawsuit involving rival splice array vendor Jivan Biologics, ExonHit said this week.

The firm said the conclusion of the reexamination paves the way for the resumption of the case between the two firms, both of which sell splice variant arrays and services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.